Minerva Neurosciences Stock Price. Everything You Need To Know About The Minerva Neurosciences Stock!
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. Since its IPO on June 25th, 2014, the company has been focused on the development and commercialization of a portfolio of product candidates designed to treat central nervous system (CNS) diseases. With a team of 9 full-time employees, the company is committed to advancing innovative treatments for patients suffering from a range of CNS disorders.
Minerva Neurosciences, Inc.’s lead product candidates include roluperidone (MIN-101) and MIN-301. Roluperidone is a compound that blocks serotonin, sigma, and α adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The firm is developing roluperidone to treat patients with schizophrenia, with a focus on blocking a specific subtype of serotonin receptor called 5-HT2A. Meanwhile, the company’s MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, which is being developed for the treatment of Parkinson’s disease and other neurodegenerative disorders.
In addition to these lead product candidates, Minerva Neurosciences, Inc. is also developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). It is important to research Minerva Neurosciences, Inc. and stay up-to-date with the latest news and developments in the biopharmaceutical industry. By keeping an eye on the stock price today and premarket, as well as shares and market cap, investors can gain valuable insight into the company’s performance and make informed investment decisions. Please note that this information is for educational purposes only and should not be considered financial advice.
Minerva Neurosciences Stock Price. Everything You Need To Know About The Minerva Neurosciences Stock! performance
- Employees 9
- Company HQ Waltham
- Website http://minervaneurosciences.com/
- NERV Asset Type Common Stock
- NERV Market Capitalization 17M
- Earnings Per Share -4.61
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Are you interested in investing in cutting-edge medical research and development? Look no further than Minerva Neurosciences, a company at the forefront of advancing treatments for neuropsychiatric disorders. As an investor from Malaysia, Thailand, Indonesia, or Vietnam, you have the opportunity to be part of their innovative journey. But how can you invest in Minerva Neurosciences from your country? At Zorion, we offer a secure investment platform where you can easily invest in real US stocks, including Minerva Neurosciences. With our investment insights and recommendations, as well as the access to educational resources, you can make informed decisions to grow your investment portfolio. Start investing in Minerva Neurosciences today and be part of the future of mental health treatment.
